Clinical Trials in Oncology

Jacob Fleming Conferences16-17 September 2010, Budapest, Hungary.
Cancer is the fastest growing healthcare priority within the pharmaceutical industry worldwide, with rising research, treatment and commercial importance. Carefully designed and efficiently conducted clinical trial can deliver new oncology drugs and diagnostics to the marketplace. There is a number of challenges in this area which remain; specifically regarding patient recruitment and regulatory issues.

Attend to explore effective patient recruitment and enrollment strategies and understand regulatory considerations surrounding clinical trials in oncology. Leading Pharma companies will share first hand experience with adaptive trial designs and case studies on conducting clinical trials in emerging markets in CEE, APAC and India.

At this conference, you will have the chance to meet true market leaders, top speakers and real experts from the pharmaceutical industry as well as from the oncology-focused institutions and organizations. Do not miss the opportunity to gain new knowledge and join us at this event of the year.

Key speakers:

  • Vice President, Chief Clinical Officer, Teva, Israel
  • Global Clinical Operations Head Oncology, Johnson & Johnson, UK
  • Chief Medical Officer, Kiadis Pharma, The Netherlands
  • Group Head Clinical Project Management, Pfizer, Germany
  • Clinical Trials Consultant to MHRA, UK
  • Clinical Trial Head, Novartis, Switzerland
  • CRUK Professor of Translational Cancer Research, University of Glasgow, UK
  • Director Clinical Research Internal Medicine Early Stage Development, Merck Sharp & Dohme, The Netherlands
  • Principal Clinical Development Scientist, GlaxoSmithKline, UK
  • Executive Director, Oncology Global Development and Medical Affairs, Bristol Myers Squibb, France
  • Group Leader Global Clinical Development Unit Oncology, MerckSerono, Germany

Key topics:

  • Recruitment and enrollment in clinical trials. Expectations and reality.
  • Current regulatory situation in relation to clinical trials in the EU
  • Biomarkers as valuable decision making tools in clinical drug development
  • How are Pharma companies implementing and managing adaptive clinical trial
  • Challenges and opportunities of conducting clinical trials in Emerging Markets

Who should attend:
Vice presidents, Global heads, Heads, Directors, Senior managers, Managers within pharmaceutical companies and oncology-focused institutions and organizations responsible for: Oncology, Clinical research and Development, Clinical trials, Clinical operations, Medical affairs, Drug development and research, Biomarkers, Imaging.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/clinical-trials-in-oncology

About the Jacob Fleming Conferences
Jacob Fleming Conferences have always been carefully designed to provide key strategic business information and the best networking opportunities for the participants. This young, dynamically growing company provides events for specialized industries including Finance, Life Science, Telecommunications, Chemical, and cross industry sectors. Extensive research, targeted speaker selection and top class venues provide a unique incentive and exceptional opportunities for the executives and experts participating in Jacob Fleming conferences. For more information, visit www.jacobfleming.com.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...